Skip to Main Content

So-called BACE drugs, biopharma’s next (and possibly doomed) hope for treating Alzheimer’s disease, have had a difficult run of form lately. First, two big trials from Merck came up short, and then another from Johnson & Johnson ran into damning safety problems.

And the latest data, on a BACE drug from Biogen, may only underline growing fears in Alzheimer’s research.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.